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ELIAS H. BOTVINICK, MD. FACC 
Son Fmnci.sco. Cnlifomia 
Long ago I was taught that good mechanics mm1 know the 
proper tool to use to perform their job effectively and 
efficiently. The principle, however, is generic, and applies to 
all vocations and professions. As physicians, we too often 
neglect or ignore this basic rule in favor of alternatives, 
possibly based on other motivations. It is this principle, 
among others, that comes to mind as I review the data and 
the implications of the report by Heller and coworkers (I) in 
this issue of the Journal. These aulhors present evidence that 
supports the application oftehoroxime to determine the state 
of coronary artery patency after thrombolytic Iherapy. They 
further imply that teboroxime is the appropriate imaging 
agent for evaluating the effects of thrombolyais. Their work 
serves as a focus for consideration of the optimal scinti- 
graphic tool in this clinical xtting. 
Hundreds of reports and reviews have been written about 
the characteristics and the real and potential advantages of 
the newly develooed. technetium-99m (wmTc)-based, myo- 
cardial perfusion imaging agents (2-4). These features r&e 
to their readv availabilitv. ootimal half-life and emission 
energy, high hose and r&l&t photon flux, kinetics and 
distribution and need not be restated here. However, those 
features bearing on their application to evaluate the effects of 
thrombolytic therapy should be considered (Table I). 
%Tc-based p&fusion agents. Teboronime belongs to a 
class of neutral, lipophilic, WmTc.containing complexes. 
This boronic acid adduct of a technetium dioxime complex is 
chemicallv and behaviorallv different from *mTc hex&s 
2.methox~-2-isobutyl-isoni&le, the cationic complex in 
widespread use as wmTc sestamibi (5,6). Although both 
agents distribute intrucellularly to the myocardium in pro. 
portion to regional perfusion, important differences in their 
pattern of distribution and kinetics must be considered in 
relation to possible applications. Although w”+Tc tcboroxime 
is more efficiently extracted over a broader range of Row 
rates than is sestamibi, this ability provides no practical 
advantage in evaluating the effects of thrombolysis. The 
rapid myocardial clearance ofteboroxime, a critical factor in 
the report of Hciler et al. (I), presents the possibility of 
repeated serial imaging at close intervals without interfer- 
ence from myocardial background (7). Yet this same feature 
makes problematic prolonged imaging with teboroxime in 
single-photon emission computed tomography (SPECT), 
where triple-headed cameras provide some advantage. The 
inordinate splanchnic localization of teboroxime also pre- 
sents difficult challenges for image ioterpretations (8). Fi- 
nally, the capability of the ageot to identify viable myocar- 
dium and differentiate it from scar must be considered. Much 
has been written suppolring the ability of thallium-201 to 
identify viable myo&ium (9, IO). Although Qume data point 
to the cootrarv (I I). much evidence relates-Tc sestamibi 
localization 10 viable myocardium (12.13) as well. Yet, 
H&r and coworkers refer repeatedly to their prior work 
(14) demonstrating the localization of teboroxime in both 
viable and infarcted repelfused myocardium. They seem to 
imply that the ideal radionuclide for evaluating infarct artery 
patency need not be a viability agent. This can be argued. 
Experimental protocol of present stody. In the experimen- 
tal protocol of the present study, what is documented and 
what is lef! to spcculalion and subsequent research? The 
study involved I5 selected patients without prior evidence of 
infarction who were undergoing elective, single-vessel MT- 
onary angioplasty of a distal vessel that “did out supply a 
significant zone of mvoearium. .” How well does this 
&up compare with.other groups studied in relation to 
thrombolytic therapy? In those groups, prior and ongoing 
infarction has been the rule. and cersistentlv dvsfunctional 
myocardium continually raises ihe questibn -of viability 
(15,16),). The present investigators (I) performed serial %Tc 
teboroxime planar imaging in two projections. Serial radio- 
nuclide administration was performed during balloon oeclu- 
sion and an average of I .6 h after successful angiaplasty. 
Although not reported, the rapid myocardial clearance of 
““Tc telwoxime would require that initial imaging be 
Tabte 1. Characteristics of Three Radionuclide Agents for 
Assessing Vessel Patency and Myocardisl Viability After 
Reowfusion Therapy 
perfamted during balloon inflation or soon afrer deflatmn. To 
provide such immediate patient access after administration 
the scintillation camera was moved into the catheterizanon 
laboratory before the study. and the lack of patient acees~ 
prevented anterior image acquisition owing to the continued 
need for Ruoroscopy. It is not surFrising that defect local- 
ization during balloon inRation cow&ted well with coronary 
regional involvement and that defect size during inAation 
decreased from 4.13 scgmentr to 0.27 segment after rcvas- 
cularization. But is this fabricated evaluation a fair measure 
of perfom~ancc in the setting of thrombolysir? Beyond these 
considerations. those wbn seek to apply teboroxime to 
assess an aspect of thromb-olytic therapy must consider the 
impact of agent kinetics on study logistics. More important. 
teboroxime characteristics must hc considered and corn- 
pared with those of other available agents in view of the fu!l 
spectrum of objectives of such evaluation. 
Aaersment of both vascular pOtency and myocardial via- 
bility. We need noninvasive methods to establish the full 
cticcta of thrombolytic therapy. The determination of ws- 
cular patency and-regional &yocsrdial viability are dual 
objectives. Although arterial patency may be of importance 
without concomitant restoralion of regional myoardial vi+ 
bility, only by evaluating viability can we Identify both 
myocardium at risk, a major justification for the intrrven- 
tion. and myoardial salvage. a variable that evnluates 
effectiveness of the intervention and helps guide future 
therapy. However. restoration of vascular patency, even to 
an infarcted territory, may also be important in reducing 
infarct expansion (17). infarct-related arrhythmia and mor- 
talitv 118.19). And these effects must not be ignored. 
inealization of the involved vessel is of v&c: however. 
it depends significantly on the anatomic distribution of the 
vascular supply and may be more difficult in the prcscnee of 
fleeting defects within the spcetrunn of unselected patients 
undergoing thrombolytic therapy. The fucus on localization 
is also exaggerated because it presents no advantage for 
tebomxime over other perfusion agents and would be imp-x- 
tant only if angiography were required. Corrclotion of pcr- 
fusion defect with anatomy could then be clarified. Cer- 
tainly, the noninvasive identification of vascular patency 
after rcperfusion therapy is important. In the setting of 
viable myocardium. vascular patency can be identified by 
demonstrating perfusion to the involved myocardial region. 
This is done well (and perhaps better) with thallium-201 and 
SmTc sestamibi (20-22) when defect size reduction on serial 
imaging generally appears to indicate both vascular patency 
and myoeardial salvage (23-26). This relation is jeopardized 
if thallium-201 is given during the hypercmic phase, early 
after rcperfusion. Here, as in the ease with 99”teboronime. 
identification of coronary patency is preserved as viability 
and regional salvage is exaggerated (23). Both agents have 
been widely used to evaluate both the need for and the 
results of corona-y angioplasty and byp;lss surgery (24.251, 
the presence of myocardium at ischemic risk (26) and the 
need for further intervention after thmmbolytic therapy (27). 
In this Letting. teboroxime administration after angioplasty 
or surgery wdl help to assess eoroiwy patency. as would 
administntion of other perfusion agents. 
Serial image evaluation. Such evaluation. as applied in 
the current study, is an advantage of the rapidly clearing 
teborowne. This rapid clearance is advantageous but not 
absolutely necessary for evaluation of arterial patency, 
which rather specifically needs the demonstration of regional 
perfusion after intervention. However, serial perfusion im- 
age cvaluwx~ is needed to assess the incremental effects of 
thromholgsis on regional perfusion and viability. These 
rlfrctr must he measured in terms of myowdium salvaged 
x well as myocardium at continued ischemic risk. Evidence 
supports the relation between thallium-201 or wmTc scsta- 
mibi localization and myocardial viability (9.10.12.13). Al- 
though “2 viability agent” may not be necessary to deter- 
mme coronary patency, it is critical for the full and 
meanmgful evaluation of the state ofthr coronary L;d and its 
subtcndcd musculature. Wackersct rd. (27) and &bbnns(Zg) 
have applied serial “mTc sestamibi imaging to at once 
demonstrdtc myoenrdial salvation and its relation to vascular 
patency after thrombolytic therapy. However, their studies 
used images obtained days apart. at the time of the interven- 
tion and some duys later. Earlier serial imaging, at a much 
shorter interval. cou!d be orchestrated with tebomrime. 
Such studies showed that, although wial reduction in defect 
size $s gcnemlly related to vase&r patency. it is sometimes 
seen with an open artery (13.14) and related infarction. 
Although thi, effect would add ambiguity to viability asscss- 
ment. it could bc of great value for identifying vascular 
prdency. Recently, St. Gibson and coworkers (29) agair. 
demonstnted thnt vascular patency to infarcted myoar- 
dium is not well idcnti8cd by~sestamibi imaging despite the 
ability of rhix acent to identify myoeardial salvaae and 
viability. - 
Rapidity oi imaging. Teboronimc localization and i:s 
relation to regional perfusion are temporally dependent. 
Although prompt imaging of administered thrdiitttt-201 is not 
critical for assessment of weasel patency, it wwld bc dcsir- 
able. and it would be absolutely necessary for evaluarion of 
bnseline perfusion before thmmbnlysis. Application ofthese 
agents to the evaluation of regional perfusion rcquircs imag- 
ing immediately after their administration. For this ieason, 
the acute evaluation of myocardium at ischemic risk using 
wmTc reboroxime or thallium-201 would require immediate 
oeeess to the patient. with prompt image acquisition afler 
rndionuclide administration. Just as fluoroscopy in this 
study limited camera aeecss during angioplasly, ucute cnrc 
of the patient with myofardial infarction oRen makes early 
image Acquisition im&ssiblc. which is a major reason that 
thallium-201 never bccamc popular for this purpose. 
Although the %Tc-based agents can be delivered in 
higher dosage. with grcatcr photon flux and more rapid 
image acquisition than can thallium-201, there is no obvious 
feature of teboroxime that puts it at an imaging advantage 
compared >uith -‘“Tc sestamibi. Whereas wmTc tebomxime 
mw be imaged quickly, images of both agents can be 
acquired rapidly. Although *Tc sestamibi imaging should 
be briefly delayed to permit background clearance if imaged 
without delay, background would be similar ::. that of 
iehoroxime. Its stable intramyocardial localization permits 
delayed assewttent of perfusion distribution at the time of 
administration. 
Because “mTc sestamibi demonstrates little mycicaidid 
washout, studies (26,27) have demonstrated the advantage of 
its administration to the patient with acute infarction scan 
after arrival at the hospital. Images acquwd hours later 
appear to reflect the state of perfusion before thrombolytic 
therapy. Subsequent %Tc sestamibi study to assess re- 
gionsl perfusion and viability and the effect of thrombolysis 
is pewrally performed al day later. In this setting its 
persistently high photon flux makes sestamibi an ideal agent 
for SPECT reconstruction and defect localization. However. 
in the setting of recent prior evaluation, even with adjusted 
dosage, agent persistence prevents optimal rapid reevalua- 
tion for vascular patency after thrombolytic therapy. Here. 
the rapid myocardial clearance of 99mTc teboroxime may be 
advantageous. However, it tw would he problematic in the 
setting of a prior WmTc sestamibi study, and an initial WmTc 
teboroxime study on admission would he impractical be- 
cause of the issue of patient access. 
Conclusions. We must carefully delineate our objectives 
and priorities in evaluating the patient with acute infarction 
undergoing thrombolysis. We know the imaging tools avail- 
able, their advattages and weaknesses (Table 1). Cansider- 
ing factors of imaging, agent energy. distribution. half-life. 
kinetics and their relation to vessel patency and myocardial 
viability, we must choose our tool or combination of tools. 
We must apply them with developed and tested protocols. 
These protocols +ould be supported by the proper hardware 
and p&onnel LO permit thk’ir opt&l a~pli&ion in the 
emergency room or coronary care unit. Although %Tc 
teboroxime has a certain kinetic advantage, it has some 
obvious deficiencies. At this point, “-Tc sestamibi appears 
to be the most appropriate agent for evaluating the patient 
undergoing thrombolytic therapy. The findings of Heller and 
coworkers (I) suggest a role as well for WmTc tehoroxime. 
Although combinations of sestamibi and teboroxime may 
present the best possibility for the complete and timelv 
evaluation of perfusion and vessel patency in the pa&t 
receiving thrombolytic therapy, this has yet to be demon- 
strated. Certainly, teboroxime alone will not address all the 
important clinical questions in these patients. The relation 
between findings on the perfusion scintigram a~; the state of 
vascuiar patency and myocardial viahdity must be well 
delineated for nil agents. Finally, the relation between image 
findings in the acute setting and late vascu!ar patency and 
prognosis remains to be fully established. Only with this 
knowledge can we effectively apply the most approptiatt: 
scintigraphic method to this important coronary subgroup. 

